Efficacy News and Research

RSS
IRIN examines antibiotic resistance, efforts to discover new drugs

IRIN examines antibiotic resistance, efforts to discover new drugs

Deleting a single gene results in autism-like behavior

Deleting a single gene results in autism-like behavior

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

Three-step clinical pathway for CAP reduces length of hospital stay

Three-step clinical pathway for CAP reduces length of hospital stay

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Liraglutide efficacy in Japanese patients “easy” to predict

Liraglutide efficacy in Japanese patients “easy” to predict

Scientists successfully tag serotonin transporter to track movements of single molecules

Scientists successfully tag serotonin transporter to track movements of single molecules

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Researchers identify genes that influence degeneration of the hippocampus

Researchers identify genes that influence degeneration of the hippocampus

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

New drug for Type 2 diabetes results in less hypoglycaemia, less weight gain and perhaps less cardiovascular risk for patients

New drug for Type 2 diabetes results in less hypoglycaemia, less weight gain and perhaps less cardiovascular risk for patients

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

AASLD, EASL to hold special conference on therapy of HCV

AASLD, EASL to hold special conference on therapy of HCV

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

Millennium introduces novel pharmacogenetic testing

Millennium introduces novel pharmacogenetic testing

Results from Access’ MuGard Phase 4 trial on oral mucositis

Results from Access’ MuGard Phase 4 trial on oral mucositis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.